Role of acid suppression in acid-related diseases: Proton pump inhibitor and potassium-competitive acid blocker

Hideki Mori, Hidekazu Suzuki

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

Original languageEnglish
Pages (from-to)6-14
Number of pages9
JournalJournal of Neurogastroenterology and Motility
Volume25
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Proton Pump Inhibitors
Gastric Acid
Helicobacter Infections
Gastroesophageal Reflux
Peptic Ulcer
Helicobacter pylori
Potassium
Acids
Pharmaceutical Preparations
Aspirin
Anti-Inflammatory Agents
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine

Keywords

  • Gastroesophageal reflux
  • Helicobacter pylori
  • Peptic ulcer
  • Potassium
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Clinical Neurology
  • Gastroenterology

Cite this

Role of acid suppression in acid-related diseases : Proton pump inhibitor and potassium-competitive acid blocker. / Mori, Hideki; Suzuki, Hidekazu.

In: Journal of Neurogastroenterology and Motility, Vol. 25, No. 1, 01.01.2019, p. 6-14.

Research output: Contribution to journalReview article

@article{8ad8be9fdc834b9992dd485ccb4fcf1d,
title = "Role of acid suppression in acid-related diseases: Proton pump inhibitor and potassium-competitive acid blocker",
abstract = "Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.",
keywords = "Gastroesophageal reflux, Helicobacter pylori, Peptic ulcer, Potassium, Proton pump inhibitors",
author = "Hideki Mori and Hidekazu Suzuki",
year = "2019",
month = "1",
day = "1",
doi = "10.5056/jnm18139",
language = "English",
volume = "25",
pages = "6--14",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "1",

}

TY - JOUR

T1 - Role of acid suppression in acid-related diseases

T2 - Proton pump inhibitor and potassium-competitive acid blocker

AU - Mori, Hideki

AU - Suzuki, Hidekazu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

AB - Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.

KW - Gastroesophageal reflux

KW - Helicobacter pylori

KW - Peptic ulcer

KW - Potassium

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85060078036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060078036&partnerID=8YFLogxK

U2 - 10.5056/jnm18139

DO - 10.5056/jnm18139

M3 - Review article

AN - SCOPUS:85060078036

VL - 25

SP - 6

EP - 14

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 1

ER -